Allogene Therapeutics, Inc. Common Stock (ALLO) Stock Price

ALLOStock

$2.17+70.59%52W

Market Cap$749.72M

P/E—

PEG Ratio—

Div yield—

Beta0.53

ALLO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.82%

Price vs S&P 500 (4W)19.24%

VGM Score42.46

Book Value / Share (Quarterly)$1.14

P/TBV (Annual)3.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-91.70%

Cash Flow / Share (Quarterly)$-0.45

Price vs S&P 500 (YTD)36.22%

Net Profit Margin (TTM)-269835.03%

EPS (TTM)$-0.87

10-Day Avg Trading Volume5.00M

EPS Excl Extra (TTM)$-0.87

EPS (Annual)$-0.87

ROI (Annual)-65.25%

Net Profit Margin (5Y Avg)-3191.05%

Cash / Share (Quarterly)$1.09

ROA (Last FY)-45.90%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-53.63%

Operating Margin (TTM)-274487.82%

Cash Flow / Share (Annual)$-0.65

P/B Ratio2.46x

P/B Ratio (Quarterly)2.13x

Net Income / Employee (Annual)$-1,272,600

EV / Revenue (TTM)3323.97x

ROA (TTM)-41.63%

EPS Incl Extra (Annual)$-0.87

Current Ratio (Annual)7.93x

Quick Ratio (Quarterly)9.47x

3-Month Avg Trading Volume7.84M

52-Week Price Return70.59%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$7.68

P/S Ratio (Annual)31142.35x

Asset Turnover (Annual)0.00x

52-Week High$4.46

Operating Margin (5Y Avg)-3267.44%

EPS Excl Extra (Annual)$-0.87

CapEx CAGR (5Y)-64.23%

26-Week Price Return-10.57%

Quick Ratio (Annual)7.74x

13-Week Price Return3.57%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.65x

Enterprise Value$654.82M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-30.18%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1168850.00%

Cash / Share (Annual)$1.09

3-Month Return Std Dev61.15%

Net Income / Employee (TTM)$-1,272,600

ROE (Last FY)-65.25%

EPS Basic Excl Extra (Annual)$-0.87

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.87

Receivables Turnover (Annual)0.01x

ROI (TTM)-57.07%

P/S Ratio (TTM)3477.83x

Pretax Margin (5Y Avg)-3192.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.68

Price vs S&P 500 (52W)52.28%

Year-to-Date Return48.18%

5-Day Price Return0.00%

EPS Normalized (Annual)$-0.87

ROA (5Y Avg)-41.84%

Net Profit Margin (Annual)-1170863.64%

Month-to-Date Return7.98%

Cash Flow / Share (TTM)$-2.12

EBITD / Share (Annual)$-0.89

Operating Margin (Annual)-1241813.64%

ROI (5Y Avg)-53.63%

EPS Basic Excl Extra (TTM)$-0.87

P/TBV (Quarterly)3.28x

P/B Ratio (Annual)1.05x

Pretax Margin (TTM)-269835.03%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)0.78%

Beta0.53x

Revenue / Share (TTM)$0.00

ROE (TTM)-57.07%

52-Week Low$1.04

vGradeD

mGradeB

vgmGradeC

ALLO Earnings Surprise History

Q2 25-0.22est. -0.27

Q3 25-0.19est. -0.23

Q4 25-0.17est. -0.22

Q1 26-0.18est. -0.18

Q2 26-0.13est. -0.15

ALLO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

4.20

4.16

4.22

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALLOAllogene Therapeutics, Inc. Common Stock	D	—	B	$2.17
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Allogene Therapeutics, Inc. Common Stock

Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf allogeneic CAR T-cell therapies for cancer and autoimmune diseases. Its genetically engineered, donor-derived T-cell products offer broader patient eligibility and manufacturing scalability compared to autologous therapies. The pipeline targets lymphoma, leukemia, solid tumors, and autoimmune disorders, with revenue generated from collaborations and licensing agreements.